Nonalcoholic fatty liver disease (NAFLD), typified by fat deposition in the liver that is not ascribed to alcohol consumption, can manifest as nonalcoholic fatty liver (NAFL) or nonalcoholic steatohepatitis (NASH). When compared with NAFL, the risk of progression to cirrhosis is substantially higher with NASH. A Markov population model designed to forecast disease progression classified approximately 20% of NAFLD cases in the United States in 2015 as NASH. Advanced fibrosis is identified in a subset, with an estimated 20% of the NASH population exhibiting F3/F4 fibrosis consistent with advanced liver disease. Patients with advanced fibrosis, including cirrhosis, are at greater risk for serious liver-related consequences.1
Distribution of NASH population by fibrosis stage in the US in 2015, using a Markov population model1*
NASH, nonalcoholic steatohepatitis; US, United States.
*Depiction of “early fibrosis” and “advanced fibrosis” for graphical purposes; based on modelling of the annual estimated number of incident NAFLD cases in 2015.
1. Estes C, Razavi H, Loomba R, Younossi Z, Sanyal A. Modeling the Epidemic of Nonalcoholic Fatty Liver Disease Demonstrates an Exponential Increase in Burden of Disease. Hepatology. 2018;67(1):123-133.
Sponsored by Intercept Pharmaceuticals, Inc.
Please click on Next tab to advance through activity.
Tell us what you think about Healio.com »
Get the latest news and education delivered to your inbox
©2020 Healio All Rights Reserved.